+44 20 8123 2220
info@marketpublishers.com

Global Cancer CDK Inhibitors Market & Clinical Pipeline Outlook 2022

https://marketpublishers.com/r/G0B58882B6EEN.html
Date: November 2017
Pages: 150
Price: US$ 2,200.00 (Single User License)
ID: G0B58882B6EEN

Abstracts

Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.

“Global Cancer CDK Inhibitors Market & Clinical Pipeline Outlook 2022” report gives comprehensive insight on clinical and non-clinical parameters related to emergence and growth of CDK inhibitors in cancer therapy. As per report findings, CDK inhibitors have emerged as new growth frontier for the organizations involved in the research, development, licensing and commercialization of targeted cancer therapies. There are 2 CDK inhibitors commercially available in the market for the treatment of cancer and more than 45 CDK inhibitors are in various phases of clinical pipeline.

“Global Cancer CDK Inhibitors Market & Clinical Pipeline Outlook 2022” report highlights:

Selectivity & Working Mechanism of a Cancer CDKs Inhibitor

Recent Advances in the CDKs Related Cancer Therapy

Global Cancer CDK Inhibitors Clinical Trials Insight: 45 Drugs in Pipeline

Market Opportunity Assessment: More Than US$ 20 Billion (2022)

Price Analysis of Cancer CDKs Inhibitors:

Sales Analysis of Available Drugs: More Than US$ 2 Billion (2017)

+44 20 8123 2220
info@marketpublishers.com

The Cyclin Dependent Kinase (CDK) Inhibitors have recently emerged as one of the most promising therapeutics in the cancer pharmaceuticals segment. The progress in the scientific and technical knowledge of how the cell cycle works, pathways involved in normal and tumorous cells and the role of cyclin in tumor cell formation (Tumorigenesis) has led to an excellent boost in the research and development of special molecules or inhibitors which can prevent tumorigenic processes in effected cells.

Cyclin Dependent Kinase (CDK) Inhibitors are considered as promising and immensely effective targeted therapy of the future as it aims at targeting the tumor cell formation at its root level, before it can progress to affect other healthy cells of the body. In addition, it has opened up multiple opportunities and avenues for the life sciences industry to work upon due to the vast diversity and variations seen in the CDK pathways and their specific role and response in various types of tumors, thus suggesting the need of different types of inhibitors for different cancer therapies.

Currently, Pfizer’s Ibrance is the only successfully market drug that has shown impressive growth in within two years of its introduction into the cancer therapy segment. Ibrance or Palbociclib first received an accelerated approval in February 2015, becoming the first CDKs inhibitor to receive approval for breast cancer therapy. In just two years Ibrance has shown excellent growth with time which is sure to make Ibrance the dominant CDKs inhibitor in the breast cancer therapy segment.

The recent advances in the discovery of newer cyclin pathways and their inhibitors have opened up new avenues in the CDKs therapy market. Multiple companies are now currently working on various therapeutics that have shown some kind of novel response in stopping or inhibiting the cell cycle. While it is obvious that Pfizer’s Ibrance is currently the most effective drug in breast cancer tumor management, it is expected that Eli Lilly and Novartis are currently working on much better therapeutic having higher overall efficacy than the Ibrance.

A strong clinical pipeline presents an encouraging scenario regarding the future of a particular therapeutic like the CDK inhibitor. The intense research and development in the CDK inhibitor segment has led to many of these newly discovered compounds showing excellent results in various phase of the clinical trials. While very few CDKs have come out of the clinical pipeline and showed excellent commercial success, many of the inhibitors are anticipated to be a blockbuster drug once they come out of the clinical pipeline.

With the advancement in science and further knowledge about the technical know-how

+44 20 8123 2220
info@marketpublishers.com

of the cyclin dependent kinase and cell cycle, the ability and potential of CDKs inhibitor as cancer therapeutic is bound to improve. Previous success of approved CDKs inhibitors like Ibrance has shown the immense market potential of the CDKs inhibitor market which largely remains untapped, especially in the developing countries which are bound to show an increased demand for effective cancer therapeutic like the CDKs in the future.

+44 20 8123 2220
info@marketpublishers.com

Contents

+44 20 8123 2220
info@marketpublishers.com

+44 20 8123 2220
info@marketpublishers.com

14. COMPETITIVE LANDSCAPE

+44 20 8123 2220
info@marketpublishers.com

List Of Figures

LIST OF FIGURES

+44 20 8123 2220
info@marketpublishers.com

+44 20 8123 2220
info@marketpublishers.com

List Of Tables

LIST OF TABLES

COMPANIES MENTIONED

Amgen
Anygen
Astex
Bayer Pharmaceuticals
BioCAD
Cyclacel
Eli – Lilly
G1 Therapeutics
Nerviano Medical Science
Merck
Pfizer
Piramal Life
Syros Pharmaceuticals
Sanofi-Aventis

+44 20 8123 2220
info@marketpublishers.com

I would like to order

Product name: Global Cancer CDK Inhibitors Market & Clinical Pipeline Outlook 2022

Product link: https://marketpublishers.com/r/G0B58882B6EEN.html

Price: US$ 2,200.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:
info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/G0B58882B6EEN.html